Avo vs Ceribell

Ceribell's purchase terms set a one-year initial term that auto-renews unless the hospital gives 90 days' notice, with fees as specified in each order. A neuro ICU or emergency department gets the point-of-care EEG headband, and the vendor describes its Clarity software as estimating seizure burden every 10 seconds from the prior five minutes. Ceribell holds 16 FDA 510(k) clearances, including Seizure Detection Software (K241589) and the Delirium Monitor System (K251936), and the company says CMS set a new-technology add-on payment of up to $2,171 for the delirium solution from October 1, 2026. It is public, with $28.1M in second-quarter 2026 revenue and 712 active accounts. Avo is a New York company that raised a $10M Series A in March 2026 and sells guideline pathways inside the EHR. Its homepage and press release make no FDA claim, and an openFDA search under its names returned no Avo device. The EEG headband sits in a neurocritical care director's budget and the guideline pathways in a clinical standards team's, so the two are never weighed against each other.